GENFIT Exhibits a Strong Presence at DALM 2007

During the XVIth International Symposium on Drugs Affecting Lipid Metabolism (DALM), the significant role that PPARalpha plays in addressing the multifactorial nature of cardiometabolic disease has been highlighted.

Lille (France), Cambridge (Massachusetts, USA), New-York (NY, USA) October 9, 2007 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company committed to drug discovery and development in the field of cardiovascular, inflammatory, and metabolic diseases presented its scientific strategy to address the multifactorial nature of cardiometabolic disease at the XVIth International Symposium on Drugs Affecting Lipid Metabolism (DALM) held in New York City last week. The DALM conference gathered the most eminent researchers in the field from both academia and industry.

During the four-day conference, some of the most current therapies for the treatment and prevention of lipid metabolism diseases were presented. Multiple therapeutic approaches were proposed to address individual risk factors during this exciting Symposium. In particular, the targeting of PPARs by "Selective PPAR Modulators" (SPPARMs) took the center stage has a great potential to address cardiometabolic disease.

Dean W. Hum, Ph.D., Executive Vice President, Chief Scientific Officer at Genfit reported : *" It is clear that cardiometabolic disease remains a major worldwide health challenge. However, significant advances have been made in our understanding of the disease and the therapeutic strategies to be undertaken. Despite the success of statin therapy which has a major activity in reducing LDL-C, there remains a residual risk of cardiovascular disease, which can be addressed by decreasing the burden of elevated triglycerides, reduced HDL-C and a proinflammatory state. As was discussed by Pr. P.J. Barter, Pr. H.B. Brewer, Pr. D.J. Rader and Pr. J-C Fruchart, President of the International Atherosclerosis Society (IAS) and Chairman of GENFIT's Supervisory Board, drug candidates that address these risk factors such as those selectively targeting PPARs are a very promising new generation of drugs to address the residual risk in an efficient and safe way."*

In the course of the plenary session of the DALM conference, Professor Jean-Charles Fruchart presented the latest data on GFT505, describing the positive effects of this compound being developed by Genfit and currently in Phase II clinical trials for the treatment of dyslipidemia and atherosclerosis. He also presented recent advances of the SPPARM approach and its effectiveness in the selection of mixed PPAR agonists.

Jean-François Mouney, Chairman of GENFIT's Management Board, added : *" The identification of selective nuclear receptor modulators, which is a major focus at Genfit, is a novel approach to discover compounds that can differentially regulate target genes, and therefore provides the opportunity to identify drug candidates with optimal efficacy/side-effect ratios. We are convinced that the development of drug candidates such as the SPPARM compound GFT505, our proprietary product currently in Phase II clinical trials, is well-positioned to provide a safe and efficient treatment ".*

About the Selective Nuclear Receptor Modulators (SNuRMs) and GFT505 : GFT505 is the most advanced molecule of a new generation of drug candidates developed by GENFIT, which aim at the prevention of the global cardiometabolic risks. Stemming from the Selective Nuclear Receptor Modulator (SNuRM) platform developed by GENFIT, this new generation of drug candidates has a sophisticated mechanism of action. These compounds are able to differentially recruit cofactors to the nuclear receptor, which subsequently lead to differential regulation of genes and biological effects. Therefore, the ability to identify and profile the activity of SNuRMs is a powerful approach for selecting innovative drug candidates with improved efficacy and diminished side-effects. These pluripotent and multimodal molecules have significant positive effects on obesity, insulinresistance and diabetes, atherosclerosis, inflammation, and the lipid triad (increasing of HDL cholesterol, lowering of triglycerides and LDL cholesterol).

About GENFIT

An emerging biopharmaceutical company, GENFIT studies the regulation of genes implicated in the most widespread diseases. GENFIT's scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT's programs, conducted in partnership with industrial pharmaceutical companies such as SANOFI-AVENTIS, PIERRE FABRE, SOLVAY, MERCK SERONO, and SERVIER deal with the most prevalent metabolic and inflammatory diseases. GENFIT's internal drug discovery and development focuses on global cardiometabolic risk, attacking several pathologies (atherosclerosis, diabetes, obesity, etc.) simultaneously, using a multimodal approach to develop single molecules addressing multiple indications.

GENFIT possesses a rich and diversified pipeline of drug candidates in multiple stages of development, carried out by GENFIT internally or in partnership with a collaborator. Four molecules are currently in Phase II: 2 proprietary products and 2 molecules in partnership with Sanofi-Aventis (AVE8134 and AVE0847). In addition, another molecule in partnership with Sanofi-Aventis (AVE0897) is completing Phase I.

With facilities in Lille, France, and Cambridge (USA), the Company was founded by Jean-François MOUNEY, Chairman of the Management Board, with the scientific support of Jean-Charles FRUCHART, Chairman of the Supervisory Board. As of September 2007, its staff was comprised of 130 employees, including more than 100 scientists. Genfit is a public company listed on the Alternext of EuronextTM Paris. (www.genfit.com).

Contacts:

GENFIT
Jean-François Mouney – Chairman of the Management Board
+ 33 (0)3 20 16 40 00

Milestones – Press Relations
Bruno Arabian
+ 33 (0)1 70 08 04 13/+ 33 (0)6 87 88 47 26
milestones@milestones-fr.com